WO2022190018 - NOVEL DARPIN BASED CD123 ENGAGERS
National phase entry:
Publication Number
WO/2022/190018
Publication Date
15.09.2022
International Application No.
PCT/IB2022/052128
International Filing Date
09.03.2022
Title **
[English]
NOVEL DARPIN BASED CD123 ENGAGERS
[French]
NOUVEAUX AGENTS DE MISE EN CONTACT DE CD123 À BASE DE DARPIN
Applicants **
MOLECULAR PARTNERS AG
Wagistrasse 14
8952 Zurich-Schlieren, CH
Inventors
REICHEN, Christian
Hirzenbachstrasse 68
8952 Zurich, CH
RESCHKE, Nina
Muttenzerstrasse 60
4127 Birsfelden, CH
SCHLERETH, Bernd
Schulstrasse 82
8952 Schlieren, CH
Priority Data
63/158,539
09.03.2021
US
63/173,227
09.04.2021
US
63/265,187
09.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1880 | |
| EPO | Filing, Examination | 10141 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 638 | |
| USA | Filing, Examination | 6510 |
Total: 19757 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to recombinant binding proteins comprising an ankyrin repeat domain, wherein the ankyrin repeat domain has binding specificity for human CD123. In addition, the invention relates to nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g., acute myeloid leukemia (AML), in a mammal, including a human.[French]
La présente invention concerne des protéines de liaison recombinées comprenant un domaine de répétition d'ankyrine, le domaine de répétition d'ankyrine présentant une spécificité de liaison pour le CD123 humain. De plus, l'invention concerne des acides nucléiques codant de telles protéines de liaison recombinées, des compositions pharmaceutiques comprenant de telles protéines ou de tels acides nucléiques, et l'utilisation de telles protéines de liaison, de tels acides nucléiques ou de telles compositions pharmaceutiques dans des méthodes de traitement ou de diagnostic de maladies, telles que le cancer, par exemple, la leucémie myéloïde aiguë (LAM) chez un mammifère, notamment un être humain.